AZD0156: Potent ATM Kinase Inhibitor for DNA Damage Response Research

Executive Summary: AZD0156 (B7822) is a selective, orally bioavailable ATM kinase inhibitor with sub-nanomolar potency and >1000-fold selectivity versus other PIKK family kinases (APExBIO product page). ATM kinase regulates cellular responses to DNA double-strand breaks, affecting DNA repair, checkpoint control, and metabolic adaptation (Huang et al., 2023). Inhibition of ATM by AZD0156 disrupts DNA repair and reprograms metabolic pathways, enhancing sensitivity to DNA-damaging agents in preclinical cancer models (Huang et al., 2023). APExBIO supplies AZD0156 with validated purity (>98%) and detailed handling protocols for research use. AZD0156 is instrumental for studies on DNA damage response, synthetic lethality, and metabolic vulnerabilities in cancer research (contrasted article).

Biological Rationale

Ataxia Telangiectasia Mutated (ATM) kinase is a serine/threonine kinase of the PIKK family, vital for orchestrating the cellular response to DNA double-strand breaks (DSBs). Upon DNA damage, ATM rapidly activates signaling cascades that initiate cell cycle checkpoints, recruit DNA repair machinery, and maintain genomic integrity (Huang et al., 2023). ATM also modulates cellular metabolism, influencing glucose and amino acid uptake in response to stress (Huang et al., 2023). Dysregulation or mutation of ATM is associated with genomic instability and increased cancer susceptibility. Selective pharmacological inhibition of ATM enables researchers to dissect these pathways, providing insights for targeted cancer therapy and synthetic lethality strategies (see related review – this article provides updated evidence on metabolic effects).

Mechanism of Action of AZD0156

AZD0156 is a small-molecule, ATP-competitive inhibitor of ATM kinase. It binds selectively to the catalytic domain of ATM, blocking its kinase activity at sub-nanomolar concentrations (IC₅₀ < 1 nM in biochemical assays; see product page). AZD0156 demonstrates >1000-fold selectivity over related PIKK kinases, including ATR and DNA-PK, as established in cell-based and enzymatic profiling studies. By selectively inhibiting ATM, AZD0156 prevents phosphorylation of downstream effectors (e.g., CHK2) following DNA DSBs, disabling checkpoint activation and DNA repair. Inhibition of ATM also reprograms cancer cell metabolism, increasing macropinocytosis and nutrient scavenging under nutrient-poor conditions (Huang et al., 2023). This dual impact on genome stability and metabolic adaptation positions AZD0156 as a valuable research tool for integrated cancer biology studies.

Evidence & Benchmarks

• AZD0156 inhibits ATM kinase with sub-nanomolar potency (IC₅₀ < 1 nM) in biochemical assays (APExBIO).
• AZD0156 exhibits >1000-fold selectivity versus related PIKK kinases, including ATR, DNA-PK, and mTOR, in cell-based assays (APExBIO).
• Oral administration of AZD0156 in preclinical cancer models enhances the efficacy of DNA-damaging agents, resulting in increased tumor cell death (Huang et al., 2023).
• ATM inhibition by AZD0156 induces metabolic adaptation via increased macropinocytosis, facilitating amino acid uptake for cancer cell survival under nutrient deprivation (Huang et al., 2023).
• Combined inhibition of ATM and macropinocytosis suppresses proliferation and induces cell death in vitro and in vivo (Huang et al., 2023).
• AZD0156 is supplied by APExBIO as a solid (molecular weight: 461.56 g/mol; formula: C₂₆H₃₁N₅O₃) with >98% purity, confirmed by HPLC and NMR (APExBIO).

Applications, Limits & Misconceptions

AZD0156 is employed in cancer research to interrogate DNA damage response, checkpoint control mechanisms, and metabolic adaptation. It is a central component in studies of synthetic lethality, particularly in combination with DNA-damaging agents or inhibitors of macropinocytosis (Huang et al., 2023). The compound enables mechanistic dissection of ATM’s role in both genomic stability and tumor metabolism. Researchers leveraging AZD0156 gain insight into vulnerabilities of ATM-deficient cancers and advance precision oncology approaches. For a strategic integration of AZD0156 in translational workflows, see this article—the current piece provides updated benchmarks and explicit storage/solubility guidance not discussed there.

Common Pitfalls or Misconceptions

• AZD0156 does not inhibit ATR or DNA-PK at physiologically relevant concentrations; non-specific effects are rare at recommended doses (APExBIO).
• The compound is insoluble in water; use DMSO (≥23.1 mg/mL with warming) or ethanol (≥5.49 mg/mL) for stock solutions.
• Long-term storage of AZD0156 solutions is not advised; prepare fresh aliquots and store at -20°C for optimal stability (APExBIO).
• ATM inhibition may not induce synthetic lethality in all genetic backgrounds (e.g., p53-mutant, c-MYC-high cancers require further validation; Huang et al., 2023).
• AZD0156 is for research use only and is not intended for clinical application in humans.

Workflow Integration & Parameters

Researchers should reconstitute AZD0156 in DMSO at concentrations ≥23.1 mg/mL with gentle warming. Ethanol provides moderate solubility (≥5.49 mg/mL); water is unsuitable due to insolubility. Store lyophilized compound at -20°C; use solutions promptly and avoid repeated freeze-thaw cycles. Product B7822 from APExBIO is shipped under Blue Ice for stability. Purity is validated by HPLC and NMR, with certificates provided. AZD0156 can be combined with DNA-damaging agents or macropinocytosis inhibitors in vitro or in vivo for experimental synergy studies (Huang et al., 2023). For precision DNA repair and checkpoint modulation workflows, see the extended discussion in this article—the current article refines solubility and selectivity parameters.

Conclusion & Outlook

AZD0156 is a benchmark ATM kinase inhibitor enabling high-precision studies of DNA damage response, checkpoint control, and metabolic adaptation in cancer research. The compound’s validated selectivity, potency, and handling protocols, as provided by APExBIO, support robust and reproducible research. Ongoing clinical investigations will further clarify its translational potential. AZD0156 remains central to research exploring synthetic lethality, metabolic vulnerabilities, and next-generation cancer therapies.